Mavacoxib-d4

Mavacoxib-d4 is the deuterium labeled Mavacoxib. Mavacoxib is a selective, oral long-acting cyclooxygenase-2 (COX-2) inhibitor and a long-acting non-steroidal anti-inflammatory drug (NSAID) . Mavacoxib is used to treat pain and inflammation associated with degenerative joint disease in dogs[1].

Product Specifications

UNSPSC

12352005

Target

COX; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Immunology/Inflammation; Others

Field of Research

Inflammation/Immunology

Solubility

10 mM in DMSO

Smiles

O=S(C1=C([2H])C([2H])=C(N2N=C(C(F)(F)F)C=C2C3=CC=C(F)C=C3)C([2H])=C1[2H])(N)=O

Molecular Formula

C16H7D4F4N3O2S

Molecular Weight

389.36

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Hurst EA, et al. The selective cyclooxygenase-2 inhibitor mavacoxib (Trocoxil) exerts anti-tumour effects in vitro independent of cyclooxygenase-2 expression levels. Vet Comp Oncol. 2019 Jun;17 (2) :194-207.|[3]Cox SR, et al. Population pharmacokinetics of mavacoxib in osteoarthritic dogs. J Vet Pharmacol Ther. 2011 Feb;34 (1) :1-11.